Under the 340B rebate pilot 2027, hospitals pay full WAC for in-scope drugs and wait for the manufacturer’s rebate. 340B rebate cash flow is the money tied up in that gap, and it can run to 55 days or longer. The entities that shorten it will be the ones that submit complete claims early, not the ones that wait for the deadline.
That is the argument Holly Herring made on 340B Pulse the day after HRSA approved ten manufacturers for the pilot. Holly is Vice President of Client Services at Clearway Health and the former director of the 340B Center of Excellence at SSM Health, where she oversaw 12 340B programs. Her advice was blunt: “That 45 days is a safety net, not a target date.”
This post walks through what changes on 1 January 2027, where 340B rebate cash flow gets stuck, and what to do in the next 80 days. It draws on Holly’s episode and on HRSA’s notice 2026-15633, published in the Federal Register on 3 August 2026.
A note on status. On 9 October 2026, the American Hospital Association, the Maine Hospital Association and four hospitals sued in the District of Maine to block the pilot and asked for a temporary restraining order. As of 12 October there is no ruling. The 2025 version of the pilot was enjoined and vacated, so the outcome is genuinely open. Prepare as if 1 January holds. Most of the work below, especially claims data quality and TPA configuration, keeps its value either way.
What is the 2027 340B rebate pilot?
The 2027 340B rebate pilot is an HRSA program in which participating manufacturers pay the 340B discount as a rebate after dispense, instead of as an upfront price at purchase. Covered entities buy in-scope drugs at WAC on their 340B wholesaler account, then submit claims data to receive the difference.
Here is what HRSA confirmed on 1 October 2026:
- HRSA approved ten manufacturers, covering 21 drug approvals. Holly counted 18 primary drugs, with extended-release and other formulations making up the rest.
- The pilot takes effect on 1 January 2027.
- All ten approved plans use Beacon as the claims platform. The manufacturer bears platform costs, so Beacon is free to covered entities.
- The pilot applies only to drugs on the CMS Medicare Drug Price Negotiation Selected Drug List for 2026 or 2027, and only during each drug’s negotiated price period.
One detail is easy to miss. The pilot applies to in-scope drugs regardless of payer or indication. Commercial, Medicaid, Medicare and cash claims all count if the NDC is on the list. Treating this as a Medicare problem will understate your exposure.
Nationally, the 21 drugs are under 5.5 percent of 340B volume. That average hides wide variation. An entity with a heavy oncology, diabetes or COPD mix can sit well above it.
How does a 340B rebate purchase actually flow?
A rebate purchase moves cash out on the day you buy and brings it back only after a complete claim is paid. Holly walked through one purchase step by step, and each step has a clock attached.
| Step | What happens | The clock |
|---|---|---|
| 1. Purchase | You buy the drug at WAC on your 340B wholesaler account | Wholesaler invoice due on your payment terms |
| 2. Dispense | The drug is dispensed to an eligible patient | The 45-day submission window starts |
| 3. Submit | Your claims data goes to Beacon, usually through your TPA | At least 45 calendar days from dispense (VIII.B.1) |
| 4. Review | The manufacturer validates the claim | 10 calendar days from a complete submission (VIII.C.4) |
| 5. Pay or deny | The rebate is paid by ACH, or denied with documentation | A correction restarts the 10-day clock |
The rebate itself equals WAC less the 340B ceiling price on the day of dispense, paid at unit level.
Holly flagged a purchasing step that comes before any of this. “Those drugs will now be purchased at WAC on your 340B account,” she said, and anything bought on a separate WAC or GPO account risks having its rebate denied. Confirm with your wholesaler now that WAC prices are loaded on the 340B account.
Why is 45 days a safety net for 340B rebate cash flow?
The 45-day window is the outer limit for a complete claim, not a deadline to work toward. A claim submitted early leaves time to fix a denial before the window closes; a claim submitted late does not.
Holly put it in concrete terms. If you submit a claim on day 5, “they have several weeks to receive that rebate, or work through any corrections from potential denial.” If you submit on day 40, “they only have 5 days to work through any corrections.”
The reason is the second clock. Manufacturers have 10 calendar days to pay or deny once they receive a complete submission. If the claim comes back as incomplete, the notice is explicit: the 10-day clock restarts when the missing data arrives.
“Every time that you have to correct a claim, that 10-day clock starts over.” Holly Herring, Clearway Health
Run that forward. A claim submitted on day 38 that needs one correction may not be complete until after day 45. At that point, as Holly put it, “in most cases, I’m going to expect that those will be lost rebates.” HRSA is defining an escalation pathway for disputes, but it is not a substitute for submitting cleanly.
She added one counterweight. Submitting too fast can also hurt, because you want every eligible claim captured before it goes out. The goal is a steady daily or weekly rhythm, not a monthly batch and not a race.
What does 340B rebate cash flow really cost?
The real cost of 340B rebate cash flow is not the rebate amount. It is how long that money sits outside your organization, and whether it comes back before the wholesaler invoice is due.
Holly framed it for a CFO this way: “Any rebate dollar unpaid when the wholesaler’s invoice is due, that is cash flow. That is cash that cannot be used.”
Hypothetical example. Assumptions: $100,000 a month in WAC purchases of in-scope drugs, a 340B ceiling price averaging half of WAC, and net 30 wholesaler terms.
- The rebate owed is about $50,000 a month.
- If claims go to Beacon within a few days of dispense and pay within 10 days, most of that rebate can return before the invoice is due.
- If claims go in near day 40, or need a correction, the same $50,000 stays outstanding past the invoice date, and the entity funds the gap from its own cash.
The numbers are illustrative. The shape of the 340B rebate cash flow problem is not. Every day of delay is a day you finance the manufacturer’s discount.
How do you estimate your 340B rebate cash flow exposure?
Holly’s method for sizing the cash at stake:
- Download each manufacturer’s operational plan from the HRSA website. Each plan lists the in-scope 11-digit NDCs.
- Pull your utilization of those NDCs for each 340B entity.
- Apply the gap between WAC and the 340B ceiling price.
- Adjust for your qualification rate on those drugs.
The result will differ sharply between entities “depending on their drug mix, patient population, specialty services,” she said. Do it per entity, not per system.
Which estimate of the administrative burden is right?
Two published estimates are an order of magnitude apart. HRSA puts the burden at about $34,320 per covered entity per year. The American Hospital Association puts it at over $1 billion across 340B hospitals, roughly $370,000 per facility. The gap reflects a real disagreement about whether rebate management is a report someone runs or a revenue cycle someone owns.
Holly’s view sits closer to the second, and it bears directly on 340B rebate cash flow. She expects many entities will need IT support or an additional 340B analyst to get complete claims to Beacon on time.
What should a covered entity do before January 2027?
Covered entities should start now, not in December. “It’s not a January 1st preparedness,” Holly said. “It is an October 2nd preparedness now.” These are the moves she named.
1. Read every manufacturer’s operational plan
The approved plans are posted on HRSA’s site. Holly’s advice is to assign people to read them in full, because “there will be details within those operational plans that could be easily missed. Some of them are several pages long.” She noted in an early discussion that some plans may be unclear, or may limit the pilot to contract pharmacies. Wasted and undispensed unit instructions also differ by manufacturer.
2. Set up Beacon, even if you already have
Beacon pays by ACH. Holly flagged that it requires penny testing and verification of both the bank account and the covered entity. The trap: entities that registered in Beacon for MFP “have to re-verify all of their bank credentials. They just can’t assume, well, I’ve done all this before.”
3. Review your TPA configurations
This was her first call after the announcement. Within a single health system, each covered entity may have a different TPA configuration, and some carry a deliberate data lag between the EMR or pharmacy and the TPA. Under a fixed 45-day window, that lag now costs money. “One of the things that is keeping me up at night right now,” she said, “is TPAs are sometimes set up unique to a covered entity.”
4. Ask your wholesaler about payment terms
If your terms are short, ask whether they can be extended so the rebate returns before the invoice falls due. Terms vary widely, so check each 340B account.
5. Get the claims data right on the first pass
The notice limits what manufacturers can ask for. Data requests are restricted to a defined list of pharmacy and medical claim fields, purchasing and encounter data may not be requested, and for uninsured or cash-paying patients the BIN, PCN and health plan fields may be marked “CASH”. Map each field to its source in your TPA, EMR and pharmacy systems before January.
Do not miss 16 December
The notice allows up to two unreplenished accumulated packages, with a 15 calendar day grace period before the effective date (VIII.C.3). In practice, that makes 16 December the first date that matters, not 1 January.
Who is most exposed to the rebate model?
Entities with heavy oncology populations face the sharpest patient impact. Holly pointed out that “many of those drugs are drugs that treat oncology,” and that prescription assistance programs funded by 340B savings often support exactly those patients.
When 340B rebate cash flow slows, the programs those savings fund come under pressure. Her advice is to identify which services depend on savings from in-scope drugs, and to plan how to keep the impact from reaching patients.
Small teams are exposed in a different way. Holly’s advice for entities short on staff is to get their TPA on a call now and ask how it will support claim delivery to Beacon, automate whatever can be automated, and then check that automation more than once.
How do denials work under the 2027 pilot?
Under the 2027 pilot, a manufacturer must pay or deny within 10 calendar days of a complete submission, and every denial must come with a rationale and specific documentation (VIII.C.5).
The notice also limits what a manufacturer can deny for. A rebate may not be denied on grounds of:
- eligibility
- diversion concerns
- Medicaid duplicate discount concerns
- a perceived lack of WAC purchases
A manufacturer with those concerns must raise them with HRSA or use audits and administrative dispute resolution. Covered entities can report denial problems to [email protected].
Holly sees the 10-day rule as both protection and pressure: “Now they expect when they should receive payment… There were no safety guardrails around that.” The open question is the denial rate. “Right now, we can’t estimate what the denial rate is going to be on these claims,” she said.
Where she sees a role for automation is good faith inquiries inside Beacon, so that “somebody’s not having to go in and click and copy and paste” a standard response.
How will you know the pilot is working after 90 days?
Holly named four measures to track from the first quarter, rather than waiting for HRSA’s evaluation, due by April 2028:
- Expected versus realized rebates, per manufacturer
- Denial rates, and the reasons given
- Payment delays past the 10-day standard
- Displaced work: what your 340B team stopped doing because the rebate work took its time
The last one is the one most teams will skip. “You can’t let this get in the way of other competing priorities within your health system and patient care,” she said.
Frequently asked questions
What is 340B rebate cash flow?
340B rebate cash flow is the cash a covered entity has outstanding between buying an in-scope drug at WAC and receiving the manufacturer’s rebate under the 2027 pilot. It can reach 55 days or more, and incomplete claims extend it.
How long do covered entities have to submit 340B rebate claims?
Covered entities have at least 45 calendar days from the date of dispense to submit claims data under the 2027 pilot (HRSA notice 2026-15633, VIII.B.1). Submitting early leaves time to correct a denial before the window closes.
How long do manufacturers have to pay a 340B rebate?
Manufacturers must pay or deny within 10 calendar days of a completed data submission (VIII.C.4). If the submission is returned as incomplete, the 10-day clock restarts once the missing data is provided.
Do covered entities pay to use Beacon?
No. The manufacturer bears platform costs, so Beacon is free to covered entities. Entities must still complete registration, bank verification and penny testing before they can receive payments.
Does the 340B rebate pilot only apply to Medicare claims?
No. The 2027 pilot applies to in-scope drugs regardless of payer or indication. Commercial, Medicaid, Medicare and cash claims count if the NDC is on the CMS selected drug list and in its negotiated price period.
Can a manufacturer deny a rebate for suspected diversion?
No. The notice bars denials based on eligibility, diversion, Medicaid duplicate discount concerns or a perceived lack of WAC purchases (VIII.C.5). Those concerns go to HRSA, audits or dispute resolution.
Is the 2027 rebate pilot certain to start on 1 January?
Not certain. The AHA, the Maine Hospital Association and four hospitals sued on 9 October 2026 and asked for a temporary restraining order. As of 12 October there is no ruling. Work on claims data quality and TPA setup keeps its value either way.
Get your 340B rebate cash flow under control before January
The 2027 pilot rewards the covered entities that treat rebate submission as a daily revenue cycle, not a monthly report. That means complete claims on the first pass, a TPA set up without lag, Beacon verified, and a CFO who can see the float.
NorthArc Health is a 340B consulting and technology company that builds custom Agentic AI solutions for covered entities. We help teams map their claims fields to Beacon, catch incomplete data before it restarts the clock, and track every rebate from dispense to deposit, while the judgment stays with your team.
Talk to NorthArc about rebate readiness
Listen to Holly Herring’s full episode on 340B Pulse, and read HRSA’s notice 2026-15633 in the Federal Register.
